Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

Artificial intelligence systems require consistent monitoring and staffing to put in place and to keep them working well.

The FDA has approved the biologics license applications for Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, respectively.

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

The Trump Administration’s censorship extends beyond federal websites and datasets to include research to be published in academic journals.

Between 2000 and 2020, the annual age-adjusted incidence of SCLC fell from 9.0 to 4.6 per 100,000 persons. Data suggest that, in the United States, the incidence of small cell lung cancer (SCLC ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.